HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Avon

This article was originally published in The Rose Sheet

Executive Summary

Third quarter sales were up 4% to $1.9 bil., but were flat in local currency, Avon reports Oct. 28. Net income was down 7% to $163.8 mil., firm adds. U.S. revenues fell 6% to $487.3 mil. due to lower customer purchase frequency and competition, particularly from mass market companies like Procter & Gamble and Johnson & Johnson in the anti-aging skin care category, Avon CEO Andrea Jung says. Beauty sales in the region also were down 6%. U.S. operating profit declined 11% to $63.9 mil. Jung notes she will outline more specific plans to address recent weakness in the company's performance during a Nov. 15 investor meeting...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS013459

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel